The new obesity drugs work, but it's a dilemma when people have to stop taking them

The Dilemma of Stopping Ozempic-Like Obesity Drugs

The arrival of new GLP-1 agonist drugs like Zepbound, Wegovy, and Mounjaro has flipped the script on obesity treatment, bringing hope where traditional diets and exercise have often let us down. Yet, there's a catch: what happens when folks have to stop taking these meds? Whether it's due to cost, shortages, side effects, or just life getting in the way, quitting these drugs usually means the weight creeps back. And that's where things get complicated.

The Appeal of GLP-1 Agonists

Take Jonathan Meyers, for instance. His story is a prime example of these drugs' magic. After years of yo-yoing on various diets, Meyers found his groove with Zepbound, shedding 35 pounds and finally escaping the relentless hunger. This newfound peace from "food noise" is a game-changer for many who take GLP-1 agonists.

The Reality of Drug Shortages

But Meyers' joyride with Zepbound hit a snag due to supply issues. The scramble to find the drug turned desperate, with family shipping it across state lines. Many in the same boat resort to alternative sources, like compound pharmacies, or try to stretch out their doses.

The Inevitability of Weight Regain

The real kicker is the biology behind obesity. GLP-1 agonists tweak hormonal and metabolic processes, but once you stop, those processes roar back to life, leading to weight regain. Studies back this up, showing folks regain about two-thirds of their lost weight within a year of stopping. A lucky few, around 17%, manage to keep most of it off.

Chronic Treatment for a Chronic Disease

Experts like Dr. Eduardo Grunvald remind us that obesity, much like chronic conditions such as kidney disease or high cholesterol, requires ongoing treatment. The biological factors at play mean stopping the medication often leads to relapse. This underscores the need to treat obesity as a chronic condition that needs long-term strategies.

The societal impact of these drugs is another layer. Social media buzzes with tales of using obesity meds for quick, cosmetic weight loss rather than medical treatment. This can set unrealistic expectations and lead to misuse. Dr. Rekha Kumar points out that many folks talking about short-term use don’t meet the medical criteria for these drugs, which are meant for long-term obesity management.

Personalized Approaches to Discontinuation

When it's time to stop these meds, a personalized plan is crucial. This often means tapering off the drugs while ramping up dietary and lifestyle changes. Emotional support and counseling are key, as the transition can be tough. Dr. Natalie Muth notes that many patients feel anxious and lost when they can't access the medication.

The Long-Term Outlook

Some, like Meyers, turn to alternatives like compounded versions of the drugs. But these come with their own set of risks and unknowns. Meyers, for example, started using similar drugs from a compound pharmacy despite concerns about what exactly is in them and potential side effects.

Conclusion

GLP-1 agonists offer a powerful tool for weight loss and management, but stopping them is a big hurdle. The biological drive for weight regain highlights the chronic nature of obesity and the need for continuous treatment. As the medical field continues to tackle these challenges, it’s clear that a multifaceted approach—medication, lifestyle changes, and emotional support—is essential for long-term success in managing obesity.

Comments

What's behind the tech industry's mass layoffs in 2024

The tech industry is facing an unprecedented wave of layoffs in 2024, continuing a distressing trend from previous years. Executives point to various reasons, including a pandemic hiring binge , high inflation , and weak consumer demand , as the primary drivers behind these mass layoffs. However, with workforces returning to pre-pandemic levels and consumer confidence rebounding, there seem to be other factors at play that are prompting companies to downsize. This article delves into the underlying causes of the 2024 tech layoffs, the impact it has on the industry and its workers, and how companies are navigating these turbulent times. The Pandemic Hiring Binge’s Aftermath During the pandemic, the tech sector experienced a hiring surge as companies adapted to new digital demands and remote work norms. This hiring spree has since been identified as unsustainable by many industry leaders, leading to significant job cuts across the board. Nearly 25,000 tech workers were laid off in the fi

Rain, Mud, and Mayhem: Inside Burning Man 2023

Fear and Loathing in the Desert: Burning Man's Watery Odyssey Introduction: In the Belly of the Beast The 2023 Burning Man festival unfolded as a surreal odyssey in the heart of the Nevada desert. A journey that veered from exhilaration to despair, the event's narrative is retold through the lens of Earl journalism, offering a visceral and unfiltered look into the chaos and contradictions of this iconic gathering. Rain, Mud, and Mayhem: Inside Burning Man 2023 Through the Muddy Looking Glass: A Descent into Chaos Ankles Deep in Anarchy : As heavy rains deluged the Black Rock Desert, thousands found themselves plunged into a quagmire of ankle-deep mud, where the thin veneer of civilization rapidly dissolved. It was a baptism by muck, where attendees struggled to navigate a treacherous landscape that mirrored their own inner turmoil. Organizers on the Brink : The festival's organizers, faced with the unexpected onslaught of nature, teetered on the precipice of disaster

What is Arweave Crypto: AR Coin Explained In Details.

The US National Archives were detected changing a 2017 photograph in January 2020. This was and is a major issue because archiving is about preserving information without modifying it. Arweave is a crypto initiative that has partnered with major cryptocurrencies to forever retain their transaction history. What is Arweave? What are its latest updates? Why is its AR coin poised to become one of the most desirable cryptocurrencies?

The End of the Affair? Not for Eric Schmidt.

The Tangled Web of Eric Schmidt's Personal Affairs Eric Schmidt, the former chief executive of Google, has lived a life that could rival any high-stakes soap opera. His professional acumen is undeniable, but his personal life has been a labyrinth of relationships, legal wranglings, and financial settlements. When Schmidt's affair with Marcy Simon, a New York-based public relations executive, became public, it set off a chain of events that has taken more than a decade to unravel. This story is a testament to the complex interplay of love, power, and money in the lives of the elite. In the mid-2000s, Schmidt and Simon were seen together frequently, from the French Riviera to Fire Island. Speculation ran rampant when Simon was spotted with a large yellow diamond ring. Would Schmidt leave his wife and marry Simon? The answer was no. Schmidt moved on to other girlfriends, but the relationship with Simon rekindled in the late 2000s before finally ending in 2014. By 2014, Schmidt an

America's retirement age of 65 is "crazy," BlackRock CEO says

Rethinking Retirement: Is 65 Too Young to Retire? The Burden of an Aging Population on the U.S. Retirement System The threadbare fabric of the U.S. retirement system is succumbing to the unyielding stress of a stark demographic evolution. Americans are living longer, far surpassing the biblical threescore years and ten with a nonchalant ease, and with this extended longevity comes a period of retirement that stretches the financial and structural capabilities of what was once considered a robust support mechanism. The Anachronism of the Retirement Age Imagine, if you will, the grainy, sepia-toned days of the Ottoman Empire, their echoes barely audible in the bustling modernity of the 21st century. Yet, from this seemingly distant past emanates our contemporary benchmark for the retirement age – the arbitrary epoch of 65 years old. Out of sync with today’s realities, this figure stands as a glaring anachronism, a historical artefact that fails to mesh with the fabric of the present time

Companies — profitable or not — make 2024 the year of cost cuts

In an economic climate marked by a notable pullback from Americans amid a period of aggressive inflation, the largest U.S. corporations are initiating widespread job reductions and expense curtailments. This proactive stance towards cost rationalization is being adopted irrespective of a company’s profitability status, signifying a strategic pivot aimed at ensuring sustainable operations and financial health. Tackling Aggressive Inflation Through Strategic Cost Reductions The Wave of Job Reductions and Expense Management In attempting to navigate through the headwinds of inflation, companies are increasingly opting for cost-cutting measures and layoffs , signaling a year geared towards financial prudence and operational efficiency. From tech giants to traditional industrial players, the trend spans various sectors, illustrating a collective effort to bolster quarterly operating income amidst challenging economic conditions. Embracing Cost Optimization Strategies Businesses are impleme

Big Lots closing dozens of stores, putting survival in question

Big Lots Faces Economic Challenges Amid Store Closures and Financial Strain Overview of Current Financial Struggles Ohio-based discount retailer Big Lots has announced plans to close between 35 and 40 stores by the end of the year, as detailed in a recent filing with the U.S. Securities & Exchange Commission (SEC). This decision stems from the company's ongoing financial difficulties, highlighted by a substantial net loss and declining sales. Financial Performance and SEC Filing Details In an extensive 280-page filing last month, Big Lots expressed "substantial doubt about the Company's ability to continue." This declaration is a response to the financial pressures exacerbated by inflation and a significant reduction in consumer spending. The company's fiscal troubles were starkly illustrated in its first-quarter results for 2024, ending May 4. During this period, Big Lots reported a net loss of $205 million, with net sales dropping 10.2% compared to the sam

Articulated

Search This Blog